Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2016.08.038
Abstract: A critical unmet need in advanced prostate cancer (PCa) management is how to best sequence the available lifeprolonging therapies to maximize clinical benefit for the individual patient and, in particular, to identify those men most… read more here.
Keywords: benefit; patients positive; abiraterone enzalutamide; prostate cancer ... See more keywords
[Adverse drug reactions profiles for abiraterone and enzalutamide: A pharmacovigilance descriptive analysis].
Sign Up to like & getrecommendations! Published in 2020 at "Therapie"
DOI: 10.1016/j.therap.2020.12.012
Abstract: OBJECTIVE The aim of this study was to describe the profile of adverse drug reactions (ADRs) observed with abiraterone and enzalutamide, based on cases registered in the French regional pharmacovigilance centres to identify potential pharmacovigilance… read more here.
Keywords: risk; drug reactions; abiraterone enzalutamide; drug ... See more keywords
Adoption of Abiraterone and Enzalutamide by Urologists.
Sign Up to like & getrecommendations! Published in 2019 at "Urology"
DOI: 10.1016/j.urology.2019.05.012
Abstract: OBJECTIVE To investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists. METHODS… read more here.
Keywords: enzalutamide urologists; abiraterone enzalutamide; enzalutamide; adoption abiraterone ... See more keywords
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-3471
Abstract: Purpose: While the detection of AR-V7 in circulating tumor cells (CTC) is associated with resistance to abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), it only accounts for a minority of this… read more here.
Keywords: abiraterone enzalutamide; cin; circulating tumor; treated abiraterone ... See more keywords
Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155220929414
Abstract: Background Two new drugs, abiraterone and enzalutamide, had recently shown beneficial effects on survival in patients with metastatic castration-resistant prostate cancer. We systematically reviewed the efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant… read more here.
Keywords: prostate; abiraterone enzalutamide; metastatic castration; castration resistant ... See more keywords
Antitumor activity of abiraterone, enzalutamide, and docetaxel following treatment with diethystilbestrol in castration-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.6_suppl.e581
Abstract: e581Background: Docetaxel and Next-Generation Anti-Androgens (NGAA) including abiraterone and enzalutamide represent the standard of treatment for patients with castration-resistant prostate cancer (CRPC). Treatment sequencing of these agents is a challenge. Recent studies identified cross-resistances between… read more here.
Keywords: treatment; abiraterone enzalutamide; prostate cancer; castration resistant ... See more keywords
Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.16
Abstract: 16Background: The CARD NCT02485691 study reported superior rPFS and OS with CBZ vs abiraterone or enzalutamide in patients with mCRPC who progressed on docetaxel and within 12 months on a previous ... read more here.
Keywords: abiraterone enzalutamide; study; pain response; card ... See more keywords
Comparative cardiotoxicity of the novel hormonal agents abiraterone and enzalutamide in metastatic castration-resistant prostate cancer using real-world data.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.62
Abstract: 62Background: Novel hormonal agents (NHAs) such abiraterone (ABI) and enzalutamide (ENZA) have demonstrated similar survival benefits against placebo groups in their respective clinical trials lead... read more here.
Keywords: novel hormonal; abiraterone enzalutamide; agents abiraterone; cardiotoxicity novel ... See more keywords
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2021 at "PLoS ONE"
DOI: 10.1371/journal.pone.0253021
Abstract: Introduction Radium-223, abiraterone, and enzalutamide have each been shown to significantly improve survival as monotherapy in patients with metastatic castration-resistant prostate cancer. However, effects of combination radium-223 plus abiraterone or enzalutamide on survival and safety… read more here.
Keywords: abiraterone enzalutamide; radium 223; metastatic castration; castration resistant ... See more keywords
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.20028
Abstract: Background Abiraterone and enzalutamide are currently approved for mCRPC patients. Both drugs have distinct mechanisms of action and may have different toxicity profile. There are limited data comparing the side effects of abiraterone and enzalutamide.… read more here.
Keywords: risk; grade; meta analysis; analysis ... See more keywords
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.24888
Abstract: Background Statins may potentiate the effects of anti-hormonal agents for metastatic castration-resistant prostate cancer (mCRPC) through further disruption of essential steroidogenic processes. We investigated the effects of statin use on clinical outcomes in patients with… read more here.
Keywords: cancer; statin use; abiraterone enzalutamide; use ... See more keywords